Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Hamill Laura reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc reported that director Laura Hamill received a grant of 1,605 restricted stock units, each representing one ordinary share, for no cash consideration. These units vest in full on July 23, 2027, subject to continuous service, bringing her direct holdings to 8,538 ordinary shares.
Kennedy Patrick reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Patrick Kennedy reported a grant of 1,605 restricted stock units, each representing one ordinary share, under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to continuous service and conditions, the units vest in full on July 23, 2027, bringing his direct holdings to 8,307 ordinary shares.
Smith Mark Douglas reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Mark Douglas Smith reported an equity compensation grant of 1,605 restricted stock units, each representing a right to receive one ordinary share. The award was made at $0.0000 per share under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to continuous service and other conditions. Following this grant, Smith directly holds 11,285 ordinary shares.
Cook Jennifer E. reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc director Jennifer E. Cook received a grant of 1,605 restricted stock units, each representing one ordinary share, at a reported price of $0.0000 per share. Granted under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan, the units vest in full on July 23, 2027, subject to continuous service and conditions. Following this award, she directly holds 12,442 ordinary shares.
Mulligan Seamus reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Seamus Mulligan received an equity award covering 1,605 ordinary shares through restricted stock units under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. The units vest in full on July 23, 2027, subject to continuous service and conditions. After this award he holds 1,184,633 ordinary shares directly, plus 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family.
McSharry Heather Ann reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Heather Ann McSharry received a grant of 1,605 restricted stock units representing contingent rights to ordinary shares. The award was issued under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to continuous service and certain conditions. Following this grant, McSharry is reported to hold 20,054 ordinary shares directly.
ENRIGHT PATRICK G reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Patrick G. Enright received a grant of 1,605 restricted stock units, each representing a contingent right to one ordinary share upon vesting, under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to continuous service and conditions, the units vest in full on July 23, 2027, bringing his reported holdings for this security to 22,984 shares.
RIEDEL NORBERT G reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc director Norbert G. Riedel received a grant of 1,605 restricted stock units on August 5, 2026 under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each unit represents a contingent right to one ordinary share and will vest in full on July 23, 2027, subject to continuous service and other conditions. Following the award, 8,629 ordinary shares were reported as beneficially owned by the NORBERT G. RIEDEL 2023 TRUST, and a separate indirect holding entry shows 10,630 ordinary shares held by trust.
COZADD BRUCE C reported acquisition or exercise transactions in this Form 4 filing.
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc, reported an equity compensation grant of 1,605 restricted stock units, each representing one ordinary share. The award carries a reported price per share of $0.00 and will vest in full on July 23, 2027, subject to continuous service and other conditions. Following this grant, Cozadd directly holds 362,287 ordinary shares of Jazz Pharmaceuticals.